Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 14Myeloid 8Sarcoma 1NET 1Lymphoid 1Endocrine 1Classical hematology 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1

Interventions

pembrolizumab 78Fulvestrant 76Carboplatin 74Trastuzumab 71Capecitabine 69Letrozole 62Cyclophosphamide 61Paclitaxel 60pertuzumab 52Specimen Handling 52Docetaxel 50abemaciclib 46ribociclib 44Anastrozole 35130-nm albumin-bound paclitaxel 35trastuzumab deruxtecan 34Magnetic Resonance Spectroscopy 33Blood Specimen Collection 33Tamoxifen 32sacituzumab govitecan 31exemestane 31Biopsy 31Gemcitabine 30Epirubicin 29pyrotinib 28palbociclib 28Surveys and Questionnaires 27Injections 27Drug Therapy 27eribulin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × decitabine and cedazuridine drug combination × Breast × Clear all
NCT05673200 2026-05-13

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
32 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡